Long-term changes in lean mass in postmenopausal women and the effects of osteoporosis pharmacotherapy: A 10-year longitudinal study.
Bone mineral density
Lean mass
Osteoporosis
Sarcopenia
Journal
Osteoporosis and sarcopenia
ISSN: 2405-5263
Titre abrégé: Osteoporos Sarcopenia
Pays: Netherlands
ID NLM: 101666399
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
22
11
2020
revised:
31
01
2021
accepted:
23
02
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
ppublish
Résumé
Although sarcopenia is diagnosed using appendicular lean mass (ALM), only a few long-term studies on changes in both ALM and bone mineral density (BMD) have been reported. The purposes of this study are to evaluate the changes in the parameters of lean mass and bone mass over a 10-year interval and to estimate the effects of osteoporosis pharmacotherapy on muscle. A total of 175 postmenopausal women were evaluated at baseline and after 10 years for BMD, ALM, fat mass, height, and weight. Subjects were further divided into an osteoporosis treatment group (n = 60) and a control group (n = 67) according to whether they had received pharmacotherapy for > 5 years. This was followed by propensity score matching for age, height, weight, and body mass index (BMI), and estimated parameters were compared between groups. Height, weight, ALM, and fat mass decreased significantly over 10 years (P < 0.05). However, lean mass index (LMI), derived as the ALM divided by the height squared, increased significantly (P < 0.001). BMD increased significantly with osteoporosis treatment (P < 0.05), while no significant differences were observed between the osteoporosis treatment and control groups in the changes to ALM or fat mass. ALM was decreased, while LMI was significantly increased. This contradictory result seems to be affected by age-related height loss. Thus, the effect of height loss needs to be considered when sarcopenia is evaluated longitudinally using LMI.
Identifiants
pubmed: 33869803
doi: 10.1016/j.afos.2021.02.002
pii: S2405-5255(21)00003-0
pmc: PMC8044587
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30-35Informations de copyright
© 2021 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Maturitas. 2011 Apr;68(4):331-6
pubmed: 21353405
Eur Respir J. 2014 Oct;44(4):905-12
pubmed: 25063245
Osteoporos Int. 2006 Jan;17(1):61-7
pubmed: 15995793
J Bone Miner Metab. 2016 Sep;34(5):547-54
pubmed: 26209166
J Am Geriatr Soc. 2007 May;55(5):769-74
pubmed: 17493199
J Diabetes Metab Disord. 2017 May 16;16:21
pubmed: 28523252
J Appl Physiol (1985). 1999 Oct;87(4):1513-20
pubmed: 10517786
Maturitas. 1997 May;27(1):55-60
pubmed: 9158078
J Am Med Dir Assoc. 2014 Aug;15(8):551-8
pubmed: 24703927
World Health Organ Tech Rep Ser. 2003;921:1-164, back cover
pubmed: 15293701
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
J Am Geriatr Soc. 2020 Jul;68(7):1410-1418
pubmed: 32150289
J Clin Endocrinol Metab. 2014 Nov;99(11):4336-45
pubmed: 25033068
Curr Pharm Des. 2004;10(21):2577-92
pubmed: 15320746
J Bone Miner Metab. 2013 Sep;31(5):556-61
pubmed: 23515924
J Clin Invest. 2019 May 23;129(8):3214-3223
pubmed: 31120440
Aging Clin Exp Res. 2016 Oct;28(5):895-9
pubmed: 26563287
J Appl Physiol (1985). 2000 Jul;89(1):345-52
pubmed: 10904070
Am J Epidemiol. 1998 Apr 15;147(8):755-63
pubmed: 9554417
Osteoporos Int. 2017 Oct;28(10):2781-2790
pubmed: 28733716
Clin Interv Aging. 2020 Mar 09;15:357-361
pubmed: 32210546
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
J Endocrinol. 2010 Jun;205(3):201-10
pubmed: 20197302
Gerontology. 2001 Jul-Aug;47(4):207-12
pubmed: 11408726
J Nutr Health Aging. 2015 Apr;19(4):474-80
pubmed: 25809813
Maturitas. 1998 Jun 17;29(3):247-52
pubmed: 9699196
Bone. 2017 Dec;105:276-286
pubmed: 28931495
J Clin Endocrinol Metab. 2003 Dec;88(12):5766-72
pubmed: 14671166